Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517339 | 0.90 | PDE10A (0.41) | TERTPDE10AALOX5CYP1A2CYP2C19 | |
| SCHEMBL14925257 | 0.85 | PDE10A (0.38) | TERTPDE10AALOX5CYP1A2CYP2C19 | |
| SCHEMBL14925219 | 0.82 | PDE10A (0.40) | PDE10AALOX5CYP1A2CYP2C19 | |
| SCHEMBL14925251 | 0.80 | CYSLTR1 (0.40) | PDE10AALOX5 | |
| SCHEMBL2671797 | 0.80 | ELANE (0.41) | TERTAPPELANECYP1A2CYP2C19 | |
| SCHEMBL2223334 | 0.79 | CYP1A2 (0.38) | ALOX5CYP1A2CYP2C19 | |
| SCHEMBL14925216 | 0.79 | PDE10A (0.34) | PDE10AALOX5CYP1A2CYP2C19 | |
| SCHEMBL3951224 | 0.78 | GPBAR1 (0.55) | PDE10AALOX5CYP1A2CYP2C19 | |
| SCHEMBL16246598 | 0.78 | PSMB5 (0.45) | TERTAPPPDE10AELANEALOX5 | |
| SCHEMBL14925246 | 0.78 | PDE10A (0.37) | PDE10AALOX5CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173620-B2 | BHQ-caged nucleotide probes photolysable by two-photon excitation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | TERT 683/4885APP 1386/4885PDE10A 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.